William A. Gray, M.D. FACC FSCAI
System Chief, Division of Cardiovascular Diseases of Main Line Health
President, Lankenau Heart Institute
William A. Gray, M.D., is an interventional cardiologist, board certified in internal medicine, cardiology, interventional cardiology, vascular medicine and endovascular medicine. Dr. Gray was at the Center for Interventional Vascular Therapy (CIVT) as Director, Endovascular Intervention at New York Columbia-Presbyterian Hospital from 2005-2015 before joining the Main Line Health System in Wynnewood, Pennsylvania.
Dr. Gray specializes in cardiac/structural and peripheral arterial disease diagnosis and treatment with a special interest in new, non-surgical modalities for stroke prevention (carotid stenting and left atrial appendage occlusion devices), and research into preventing the reoccurrence of disease following successful angioplasty or stenting. He has also dedicated a significant portion of the past decade of his career to the non-surgical management of mitral regurgitation.
Dr. Gray has been principal investigator for numerous clinical trials, and is routinely asked to speak at national and international conferences. He has also been a consultant and device/procedure proctor for numerous medical corporations, and has been a journal reviewer for the Journal of the American Medical Association, the Journal of the American College of Cardiology, Circulation, and Catheterization and Cardiovascular Intervention.
Dr. Gray holds a bachelor’s degree in Chemistry from Dickinson College in Carlisle, PA and graduated from Temple University’s School of Medicine in Philadelphia. Dr. Gray’s postgraduate training included an internship, residency, and Chief Residency in Internal Medicine at Brown University/Rhode Island Hospital in Providence, R.I., where he also completed a clinical/research/ interventional fellowship in Cardiology.
Dr. Gray is also a member of numerous professional organizations, including as a fellow in both the Society for Cardiovascular Angiography and Interventions and the American College of Cardiology.
Professor ANDREW HOLDEN, MBChB, FRANZCR, EBIR
Director of Interventional Radiology, Auckland Hospital
Professor Andrew Holden is Director of Interventional Radiology at Auckland City Hospital and Professor of Radiology at the University of Auckland. He is also Co-Director of the Auckland Endovascular Service. Dr Holden is on the influential RANZCR Interventional Radiology Committee, a member of IRSA (Interventional Society of Australasia) and national representative of both APSCVIR and ESGAR. He is a past examiner for the RANZCR. He holds the EBIR (European Board of Interventional Radiology) Diploma. Dr. Holden was Convenor of the successful APSCVIR 2019 Scientific Meeting in Auckland in March 2018 and is currently President of the Asia-Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR).
Dr. Holden is the author of over 100 articles in peer reviewed journals and five book chapters. His interests include vascular interventional procedures including advancedendovascular aneurysm repair techniques and revascularization in claudication and critical limb ischaemia. Other interests include interventional oncology and advanced liver imaging. To date, Dr. Holden has been involved in 50 medical device trials, many “first in man” and many as Principal Investigator. He co-directs the Vascular Intervention Research Unit at Auckland Hospital.
In 2018, Dr. Holden was recognized for his contribution to vascular and endovascular intervention by being awarded an Officer of the New Zealand Order of Merit (ONZM) medal.
SAHIL A. PARIKH, MD, FACC, FSCAI
Director of Endovascular Services, and Associate Professor of Medicine at the Columbia University Vagelos College of Physicians and Surgeons
Dr. Parikh is the Director of Endovascular Services, and Associate Professor of Medicine at the Columbia University Vagelos College of Physicians and Surgeons. His clinical practice leverages his knowledge and experience in clinical cardiovascular medicine and complex coronary and peripheral vascular inerventions. He has an active practice in cardiovascular medicine with a focus on atherosclerotic vascular disease and intervention throughout the circulation. This includes coronary artery disease, peripheral arterial disease including claudication and critical limb ischemia, renovascular disease, cerebrovascular disease and venous disease and thrombosis. He is a nationally recognized clinician educator and investigator in vascular medicine and intervention. He has won numerous teaching awards locally and co-directs several national educational programs for physicians in training and for continuing medical education in conjunction with the Cardiovascular Research Foundation (CRF), the American College of Cardiology (ACC) and the Society for Cardiac Angiography and Intervention (SCAI). His research interests focus on novel endovascular devices for the treatment of vascular disease. He has been the site and national principal investigator for several clinical trials and has authored more than 50 original manuscripts and reviews in basic and clinical cardiovascular medicine. He lectures frequently at national meetings including the Transcatheter Cardiovascular Therapeutics (TCT), ACC and SCAI amongst others.
Dr. Parikh graduated magna cum laude from Harvard College with an AB in Biomedical Sciences and Engineering and went on to earn his MD from the Johns Hopkins University School of Medicine with Phi Beta Kappa and Alpha Omega Alpha honors. He completed his internal medicine residency and chief residency at the Massachusetts General Hospital, cardiovascular medicine and interventional cardiology fellowships at the Brigham and Women’s Hospital and vascular medicine and intervention fellowship at the Massachusetts General Hospital, all teaching hospitals affiliated with the Harvard Medical School in Boston. He is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology, Vascular Medicine and Endovascular Intervention.
KRISHNA ROCHA-SINGH, M.D., F.A.C.C., F.A.H.A., F.S.C.A.I.
Chief Scientific Officer, Prairie Heart Institute
Dr. Krishna Rocha-Singh received his undergraduate medical education at the University of California, Los Angeles and completed general internal medicine at the University of Colorado and a basic science research fellowship at the Cardiovascular Research Institute at the University of California, San Francisco (UCSF) where he also completed his general cardiology fellowship before completing a fellowship in coronary and peripheral interventions at the Scripps Clinic and Research Foundation in La Jolla, California.
In 1993, Dr. Rocha-Singh joined Prairie Cardiovascular Consultants, Ltd. In Springfield, IL where he served as President of Prairie Research and Education Cooperative (PERC), founded the peripheral angiographic and wound healing core laboratory, SynvaCor. Dr. Rocha-Singh has held leadership positions within the American College of Cardiology, the Society of Cardiac Angiography and Interventions and chaired consensus writing committees for the American Heart Association. He currently serves on editorial boards and reviews for several academic journals and has authored or co-authored over 100 peer-reviewed manuscripts, book chapters, and abstracts on endovascular and interventional subjects, including manuscripts in collaboration with the US Food and Drug Administration (FDA) on medical device regulatory trial designs and the development of Objective Performance Criteria for the evaluation of medical devices and analyses of the association between paclitaxel-coated balloons and mortality.
Dr. Rocha-Singh has served as a National and International Principal Investigator for multiple clinical device trials and is a founding board member of Vascular InterVentional Advances (VIVA), a not-for-profit organization dedicated to education and research. His current research interests center on new medical device development for the transluminal administration of drug and biological therapies and the development of in-vivo translational models of vascular intimal and medial calcification. He is a frequent lecturer at national and international congresses and advises early-stage medical device companies on clinical and regulatory trial design. Dr. Rocha-Singh has over 10 issued and provisional US patents in the fields of intravascular and intramural drug delivery, endovenous stents, hypertension, and heart failure.
Craig Walker, M.D. F.A.C.C., F.A.C.A., F.A.C.P., F.S.C.A.I, F.A.S.C.I., F.C.C.P., F.I.C.A.
Founder, President, Medical Director and Interventional Cardiologist
Dr. Craig Walker completed his pre-medicine collegiate degree at Nicholls State University. He earned his doctorate from the LSU School of Medicine in New Orleans and continued his training with a cardiology fellowship at Ochsner Foundation Hospital in New Orleans and a fellowship at Harvard Medical School in Boston, Massachusetts.
Dr. Walker is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He is a fellow of the American College of Cardiology, the American College of Physicians, the American Society of Cardiovascular Interventionists, the International College of Angiology, the Society for Cardiac Angiography and Interventions, the American College of Chest Physicians and the Council on Clinical Cardiology. He is a Clinical Professor of Medicine at LSU and Tulane Medical Schools. He is Clinical Editor of Vascular Disease Management and is on the editorial board of the Journal of Endovascular Therapy, Endovascular Today, Global Vascular Digest as well as many other vascular-based journals. He is on the Scientific Board of Directors for many of the world’s largest peripheral interventional device companies.
In 1983, Dr. Walker established the Cardiovascular Institute of the South (CIS), a world-renowned practice with 17 locations throughout Louisiana and Mississippi. CIS has played a pivotal role in the clinical research and development of most new interventional technologies. Dr. Walker served as the Primary Investigator for many of these clinical trials. He has had a deep-rooted focus on improving the diagnosis and treatment of all forms of PVD with specific focus on critical limb ischemia and amputation prevention.
Dr. Walker has received numerous awards from around the world for his teaching efforts. He is an inventor and has established numerous medical companies. Dr. Walker is the author and co-author of more than 300 peer-reviewed medical articles and more than 30 book chapters.
Dr. Walker founded and is the chairman of New Cardiovascular Horizons. He established the conference to educate and train medical professionals on the latest techniques to treat coronary and peripheral vascular disease. Dr. Walker’s advocacy has included extensive educational projects in China and Japan. He has performed live cases for major conferences throughout North America, Latin America, Europe, and China. He has delivered thousands of presentations and lectures throughout the world to both lay and medical audiences. Improving the care of patients with peripheral vascular disease has been Dr Walker’s life-long mission.